PPCB
Propanc Biopharma, Inc. (PPCB) is rated D+ (1.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (F). The rating has held at D+ for 7 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | C+ (2.5) | C+ (2.5) | D- (0.9) | F (0.3) | C+ (2.6) | D+ (1.8) |
| 2026-11-07 | C+ (2.5) | C+ (2.5) | D- (1.0) | F (0.3) | C+ (2.7) | D+ (1.8) |
| 2026-10-31 | C+ (2.5) | C+ (2.5) | D- (1.0) | F (0.3) | C+ (2.7) | D+ (1.8) |
| 2026-10-24 | C+ (2.5) | C+ (2.5) | D- (1.0) | F (0.4) | C+ (2.6) | D+ (1.8) |
| 2026-10-17 | C+ (2.5) | C+ (2.5) | D- (1.0) | F (0.4) | C+ (2.6) | D+ (1.8) |